Archives

Perfusfind S.L.

Abstract A critical aspect of cardiopulmonary bypass (CPB) is achieving full anticoagulation to prevent thrombosis and consumptive coagulation (CCA). Systemic anticoagulation with heparin during CPB should be completely neutralized by..

Perfusfind S.L.

Abstract Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction characterized by thrombocytopenia and a high risk of thrombosis. Patients with HIT and a need for cardiac surgery with cardiopulmonary..

Perfusfind S.L.

Abstract Background In patients receiving extracorporeal membrane oxygenation (ECMO), standard practice is full-dose intravenous unfractionated heparin (UFH) targeting an activated partial thromboplastin time of 2·0–2·5 times baseline to reduce thrombotic..

Perfusfind S.L.

Abstract Hospital-acquired infection (HAI) is a major complication in pediatric patients on extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Infection detection is challenging, as traditional inflammatory markers..

Perfusfind S.L.

Abstract The global rise in anticoagulant use has increased the number of major bleeding events that warrant timely and effective pharmacologic reversal. Reversal strategies should be informed by the pharmacodynamic..

Perfusfind S.L.

Abstract Background: Heparin-induced thrombocytopenia (HIT) in patients who undergo cardiac surgery presents unique diagnostic and management challenges due to universal perioperative heparin exposure, postoperative platelet kinetics, and the high prevalence..

Perfusfind S.L.

Abstract Background Thromboelastometry is often used to guide coagulation management, but validation outside cardiac surgery is limited. We evaluated correlations between thromboelastometry parameters and conventional laboratory tests in noncardiac patients..

Perfusfind S.L.

Abstract Objectives To determine if the administration of coagulation products in cardiac surgery depends on the anesthesiologist’s exposure/number of cases per year, being on-call the same night as the surgery,..

Perfusfind S.L.

Abstract Effective coagulation management is pivotal to optimizing outcomes in cardiac surgery, influencing bleeding risk, transfusion requirements, and overall perioperative safety. This comprehensive review examines current strategies, limitations, and emerging..

Perfusfind S.L.

Abstract Background The contact activation system is triggered when blood comes into contact with artificial surfaces. Cardiopulmonary bypass (CPB) induces such activation, however the extent of factor XII (FXII) reduction..

Perfusfind S.L.

Abstract Objectives To compare the diagnostic performance of 4 clinical prediction scores for heparin-induced thrombocytopenia (HIT) in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Design Bicentric retrospective observational study...

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) is a life-saving intervention for patients with severe cardiac or respiratory failure, but it is associated with a high risk of thrombotic and bleeding..

Perfusfind S.L.

Abstract Objectives This systematic review and meta-analysis aimed to evaluate clinical outcomes associated with different systemic heparin protocols (conservative v standard intensity) during extracorporeal membrane oxygenation (ECMO) support. Included studies comprised both..

Perfusfind S.L.

Abstract Background Heparin-induced thrombocytopenia (HIT) in patients who undergo cardiac surgery presents unique diagnostic and management challenges due to universal perioperative heparin exposure, postoperative platelet kinetics, and the high prevalence..

Perfusfind S.L.

Abstract Introduction Bleeding and clotting phenotypes are common in patients supported with Extracorporeal Membrane Oxygenation (ECMO) and are associated with increased mortality. However, tools to distinguish bleeding from clotting phenotypes..

Perfusfind S.L.

Abstract Factor XIII (FXIII) contributes to clot stability and reduces clot susceptibility to lysis through fibrin cross-linking. Standard coagulation tests like prothrombin time and activated partial thromboplastin time do not..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) has increasingly been used in patients with refractory severe cardiorespiratory failure in recent years. The use of ECMO necessitates anticoagulation as blood passes through an..

Perfusfind S.L.

Abstract Heparin-induced thrombocytopenia (HIT) in patients on mechanical circulatory support (MCS) prior to lung transplantation poses a unique challenge of balancing thrombotic versus hemorrhagic complications. An alternative method of anticoagulation..

Perfusfind S.L.

Abstract Extracorporeal life support, such as hemodialysis, often face the risk of blood coagulation, where systemic anticoagulation with heparin is routinely administered. However, this strategy is contraindicated in patients at..

Perfusfind S.L.

Abstract Factor XII (FXII) is a central mediator at the intersection of coagulation, fibrinolysis, inflammation, and immunity. It is activated upon contact with negatively charged surfaces, triggering the intrinsic coagulation..

Perfusfind S.L.

Abstract Background: Heparin is the standard anticoagulant used during cardiopulmonary bypass (CPB). However, there are problems with heparin, including immunogenicity and variability of effect, that make a search for an..

Perfusfind S.L.

Abstract The past year has yielded important advances in coagulation and transfusion practice across cardiothoracic and vascular care. Patient blood management remains central, with growing evidence supporting restrictive transfusion thresholds,..

Perfusfind S.L.

Abstract Disseminated intravascular coagulation (DIC) has long been described as a catastrophic systemic activation of coagulation with suppressed anticoagulant and fibrinolytic pathways, culminating in macro- and microvascular thrombosis, hypoperfusion, and..

Perfusfind S.L.

Abstract Anticoagulants are widely used to prevent and treat thrombotic disorders, and continuous advances have refined their efficacy and safety. Beyond their established anticoagulant function, growing evidence indicates that some..

Perfusfind S.L.

Abstract Background Monitoring of unfractionated heparin (UFH) in critically ill patients is challenging due to disease-related alterations of the coagulation system, directly affecting conventional laboratory tests, including activated partial thromboplastin..

Perfusfind S.L.

Abstract Objectives To develop and validate, a real-time algorithm to individualize unfractionated heparin (UFH) dosing based on activated clotting time (ACT) dynamics in cardiac procedures with or without cardiopulmonary bypass..

Perfusfind S.L.

Abstract Objectives:  The parenteral anticoagulant bivalirudin has favorable safety and efficacy outcomes compared with unfractionated heparin (UFH) in pediatric patients requiring extracorporeal membrane oxygenation (ECMO), and is frequently monitored using..

Perfusfind S.L.

Abstract Background: Although unfractionated heparin (UFH) has traditionally been used for anticoagulation during extracorporeal membrane oxygenation (ECMO), bivalirudin may be preferred due to fewer complications. A prior medication use evaluation..

Perfusfind S.L.

Abstract Clinically significant bleeding is a common complication of extracorporeal membrane oxygenation (ECMO), with bleeding observed in upwards of 40% of patients. Bleeding is strongly associated with systemic anticoagulation, which..

Perfusfind S.L.

Abstract Objectives Clinical practice in anticoagulation management, particularly in heparin administration, monitoring, reversal and haemostasis, is known to differ significantly. To better characterize this variability, we conducted a Europe-wide survey..